|
KMID : 0378019910340100107
|
|
New Medical Journal
1991 Volume.34 No. 10 p.107 ~ p.113
|
|
|
Clinical Evaluation of Cefminox(Meicelin^(®)) in Infectous Disease of Genitourinary Tract
|
|
|
|
|
Abstract
|
|
|
The Cefminox(Meicelin®) has, dual. action(binding capacity to penicillin-binding protein and peptidoglycan in the outer membrane of bacteria) and it has a capacity of bacteriolysis with its structural charateristics(amino chain, D-cysteine, at 7 ?). And the drug, a broad spectum antibiotics from Gram-negative bacteria to anaerobic bacteria, have anti-bacterial activity not only in the proliferative phase but also in the resting phase. and is stable to ?-lactamase producing bacteria.
From July, 1990 to November, 1990, we evaluated the effectivity and the safety of Cefminox(Meicelin®) in 33 cases with urogenital tract infections.
The results as follows ;
1. Urogenital tract infections were complicated cystitis(18 cases, 54.5%), acute pyelonephritis(8 cases, 27.3%), urosepsis(4 cases, 12.1%) and acute prostatitis(2-cases, 6.1%).
2. Isolated organisms were E.coli(13 cases, 39.3%), Pseudomonas aeroginosa(8 cases, 24.2%), Staphylococcus aureus(3 cases, 9.1%), Enterococcal cloacae(2 cases. 6.1%), Citrobacter freundii (2 cases, 6.1%), Pseudomonas cepacia(2 cases, 6.1%), Proteus vulgaris(2 cases, 6.1%) and Klebsiella pneumoniae(1 case, 3.0%).
3. After treatment, pyuria was disappeared in 18 cases(54.5%), decreased in 9 cases(27.3%), not changed in 5 cases(15.2%) and-increased in 1 case(3.0%), so the efficacy rate on. pyuria was 81.8%. And bacteria was not cultured in 26 cases(78.8%), but, colony counts were decreased in 4 cases(12.1%) and not change in 1 case(3.0%).
4. There were no significant differences in laboratory findings before and after treatment except for mild pruritis and drug eruption in 2 cases.
5. Efficacies were excellent in 19 cases(57.6%), good in 6 cases(13.2%), fair in 5 cases(15.1%) and negligible in 3 cases(9.1%). So overall efficacy rate was 75.8%.
So. Cefminox(Meicelin®) could be used in urogenital tract infections safely and its efficacy would be more high in uncomplicated urogenital tract infections.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|